Stockreport

TRACON Pharmaceuticals and Eucure Biopharma, a Subsidiary of Biocytogen, Announce Partnership for Development of Clinical Stage CTLA-4 Antibody YH001

TRACON Pharmaceuticals, Inc.  (TCON) 
Last tracon pharmaceuticals, inc. earnings: 2/27 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: traconpharma.com
PDF YH001 is a potential best-in-class CTLA-4 antibody with enhanced ADCC and CDC effector functions YH001 is currently being dosed in multiple Phase 1 oncology trials spon [Read more]